Helene Guet-Revillet
Overview
Explore the profile of Helene Guet-Revillet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
848
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martinez-Rivera S, Guet-Revillet H, Herin F, Martin-Blondel G, Miedouge M, Billon L, et al.
Tuberculosis (Edinb)
. 2023 Oct;
143:102416.
PMID: 37844483
Whole T cell interferon gamma release assays such as QuantiFERON-TB Gold Plus (QTF-TB) are used to evaluate Mycobacterium tuberculosis complex (MTC) exposure but fail to discriminate latent tuberculosis infection (LTBI)...
2.
Pinilla M, Mazars R, Verge R, Gorse L, Paradis M, Suire B, et al.
J Exp Med
. 2023 Aug;
220(10).
PMID: 37642996
Human airway and corneal epithelial cells, which are critically altered during chronic infections mediated by Pseudomonas aeruginosa, specifically express the inflammasome sensor NLRP1. Here, together with a companion study, we...
3.
Appegren A, Boschiroli M, De Cruz K, Michelet L, Hery-Arnaud G, Kempf M, et al.
Pathogens
. 2023 Apr;
12(4).
PMID: 37111434
infects cattle and wildlife, and also causes a small proportion of tuberculosis cases in humans. In most European countries, infections in cattle have been drastically reduced, but not eradicated. Here,...
4.
Lombes A, Bonnin R, Laurent F, Guet-Revillet H, Bille E, Cattoir V, et al.
Antimicrob Agents Chemother
. 2021 Dec;
66(2):e0198321.
PMID: 34930033
In this multicentric study performed in 12 French hospitals, we reported that 26.9% (14/52) of the amoxicillin-clavulanate-resistant Proteus mirabilis isolates produced the OXA-23 carbapenemase. We found that an inhibition zone...
5.
Bemer P, Peuchant O, Guet-Revillet H, Bador J, Balavoine C, Basille D, et al.
BMC Pulm Med
. 2021 Oct;
21(1):333.
PMID: 34702233
Background: Recent studies report very low adherence of practitioners to ATS/IDSA recommendations for the treatment of nontuberculous mycobacteria pulmonary disease (NTM-PD), as well as a great variability of practices. Type...
6.
Guerin F, Dejoies L, Degand N, Guet-Revillet H, Janvier F, Corvec S, et al.
Microorganisms
. 2021 Aug;
9(8).
PMID: 34442745
The aim of this multicentre study was to determine the in vitro susceptibility to anti-anaerobic antibiotics of Gram-positive anaerobic cocci (GPAC) isolates responsible for invasive infections in humans. A total...
7.
Rousset S, Lafaurie M, Guet-Revillet H, Protin C, Le Grusse J, Derumeaux H, et al.
Drugs Aging
. 2020 Nov;
38(1):43-52.
PMID: 33145702
Objectives: Pyrazinamide (PZA) has a controversial safety profile in older patients. We aimed to assess the frequency and risk factors for adverse drug reactions (ADRs) in patients over 75 years...
8.
Guet-Revillet H, Dompmartin A, Join-Lambert O
Rev Prat
. 2020 Oct;
70(6):653-656.
PMID: 33058612
Skin microbiome: role in human health and skin inflammatory diseases. The skin barrier is a major interface between the human host and its environment. It is colonized by more than...
9.
Bouzinbi N, Marcy O, Bertolotti T, Chiron R, Bemer P, Pestel-Caron M, et al.
PLoS One
. 2020 Sep;
15(9):e0239146.
PMID: 32976521
The first objective of this study was to determine the GenoType NTM-DR assay performance for subspecies identification in Mycobacterium abscessus complex isolates. The second objective was to evaluate the GenoType...
10.
Gruzelle V, Guet-Revillet H, Segonds C, Bui S, Macey J, Chiron R, et al.
BMC Pulm Med
. 2020 Jun;
20(1):159.
PMID: 32503487
Background: Whereas Burkholderia infections are recognized to impair prognosis in cystic fibrosis (CF) patients, there is no recommendation to date for early eradication therapy. The aim of our study was...